Evaluation of Mood Disorders Under Biologics in Chronic Inflammatory Rheumatic Disease

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE BESANCON · Mar 24, 2021

Keywords

ClinConnect Summary

This clinical trial is studying how treatment with certain medicines called biologics, specifically those that block a substance called TNF-alpha, might affect mood in people with chronic inflammatory rheumatic diseases. These diseases, like rheumatoid arthritis and psoriatic arthritis, cause joint pain and inflammation, which can sometimes lead to feelings of anxiety or depression. The study aims to understand if reducing inflammation with these treatments can also help improve mood.

Adults between 18 and 80 years old with specific types of rheumatic diseases who have not used anti-TNF-alpha treatments before may be eligible to join. Participants will need to give their consent and be part of the French social security system. People who have a history of depression or are taking antidepressants, pregnant women, or those without social security coverage cannot participate. If you join, you can expect to be monitored while receiving TNF-alpha blocking treatment to see how it affects both your disease symptoms and your mood. This study is currently recruiting participants and hopes to provide better insight into how treating inflammation might also support mental well-being in people with these conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients (≥18 ; ≤ 80)
• • Patient with rheumatoid arthritis (RA) according to the ACR 2010 criteria, axial or peripheral spondyloarthritis (SpA) according to ASAS criteria, ankylosing spondylitis (AS) according to the New York criteria or psoriatic arthritis (PsA) according to CASPAR criteria
• • Signature of informed consent
• • Affiliation to a French social security or receiving such a scheme
• Exclusion Criteria:
• • Patient having previously received anti-TNFα treatment
• • Patient with previously diagnosed depressive or psychiatric pathology and / or receiving anti-depressant treatment
• • Subjects with limited legal capacity.
• • Subjects judged by the investigator to be unlikely to comply with study procedures
• • Subjects with no social security coverage.
• • Pregnant women.
• • Subjects still in the exclusion period of another study, or according to the national registry of clinical trial participants.